Tải bản đầy đủ (.pdf) (3 trang)

Andersons pediatric cardiology 1668

Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.59 KB, 3 trang )

cardiomyopathy:agenome-wideanalysis.JAm
CollCardiol.2010;55(11):1127–1135.
68.WangH,LiZ,WangJ,etal.Mutationsin
NEXN,aZ-discgene,areassociatedwith
hypertrophiccardiomyopathy.AmJHumGenet.
2010;87(5):687–693.
69.SantosS,MarquesV,PiresM,etal.High
resolutionmelting:improvementsinthegenetic
diagnosisofhypertrophiccardiomyopathyina
Portuguesecohort.BMCMedGenet.
2012;13:17.
70.HubyAC,MendsaikhanU,TakagiK,etal.
DisturbanceinZ-diskmechanosensitiveproteins
inducedbyapersistentmutantmyopalladin
causesfamilialrestrictivecardiomyopathy.JAm
CollCardiol.2014;64(25):2765–2776.
71.JensenMK,HavndrupO,ChristiansenM,etal.
Penetranceofhypertrophiccardiomyopathyin
childrenandadolescents:a12-yearfollow-up
studyofclinicalscreeningandpredictivegenetic
testing.Circulation.2013;127(1):48–54.
72.ElliottPM,D'CruzL,McKennaWJ.Late-onset
hypertrophiccardiomyopathycausedbya
mutationinthecardiactroponinTgene.NEngl
JMed.1999;341(24):1855–1856.
73.Ostman-SmithI,WettrellG,KeetonB,etal.
Age-andgender-specificmortalityratesin


childhoodhypertrophiccardiomyopathy.Eur
HeartJ.2008;29(9):1160–1167.


74.NiimuraH,BachinskiLL,SangwatanarojS,etal.
MutationsinthegeneforcardiacmyosinbindingproteinCandlate-onsetfamilial
hypertrophiccardiomyopathy.NEnglJMed.
1998;338(18):1248–1257.
75.Roma-RodriguesC,FernandesAR.Geneticsof
hypertrophiccardiomyopathy:advancesand
pitfallsinmoleculardiagnosisandtherapy.Appl
ClinGenet.2014;7:195–208.
76.LopesLR,ZekavatiA,SyrrisP,etal.Genetic
complexityinhypertrophiccardiomyopathy
revealedbyhigh-throughputsequencing.JMed
Genet.2013;50(4):228–239.
77.GirolamiF,HoCY,SemsarianC,etal.Clinical
featuresandoutcomeofhypertrophic
cardiomyopathyassociatedwithtriplesarcomere
proteingenemutations.JAmCollCardiol.
2010;55(14):1444–1453.
78.VanDriestSL,VasileVC,OmmenSR,etal.
MyosinbindingproteinCmutationsand
compoundheterozygosityinhypertrophic
cardiomyopathy.JAmCollCardiol.
2004;44(9):1903–1910.
79.FoureyD,CareM,SiminovitchKA,etal.
Prevalenceandclinicalimplicationofdouble


mutationsinhypertrophiccardiomyopathy:
revisitingtheGene-doseeffect.CircCardiovasc
Genet.2017;10(2).
80.MacArthurDG,BalasubramanianS,FrankishA,

etal.Asystematicsurveyofloss-of-function
variantsinhumanprotein-codinggenes.Science.
2012;335(6070):823–828.
81.PanS,CaleshuCA,DunnKE,etal.Cardiac
structuralandsarcomeregenesassociatedwith
cardiomyopathyexhibitmarkedintoleranceof
geneticvariation.CircCardiovascGenet.
2012;5(6):602–610.
82.LopesLR,MurphyC,SyrrisP,etal.Useofhighthroughputtargetedexome-sequencingtoscreen
forcopynumbervariationinhypertrophic
cardiomyopathy.EurJMedGenet.
2015;58(11):611–616.
83.WalshR,ThomsonKL,WareJS,etal.
Reassessmentofmendeliangenepathogenicity
using7,855cardiomyopathycasesand60,706
referencesamples.GenetMed.2017;19(2):192–
203.
84.DasKJ,InglesJ,BagnallRD,SemsarianC.
Determiningpathogenicityofgeneticvariantsin
hypertrophiccardiomyopathy:importanceof
periodicreassessment.GenetMed.
2014;16(4):286–293.



×